We’re aware that the recent national announcement about Mounjaro (tirzepatide) is generating significant public interest, which is likely to result in increased contact from patients.
We will be publishing further information when we receive it, but in the meantime please see below:
West Yorkshire ICB (Integrated Care Board) are developing a set of public FAQs and other resources which will be available in the next few weeks. In the meantime, we wanted to provide you with a short set of key messages to help inform our patients.
- Mounjaro is being introduced in a small number of GP practices as part of wider support for people living with obesity
- It is only available to a limited number of patients in the first year, based on strict NHS criteria
- Eligibility includes a BMI of 40 or more and at least four serious weight-related health conditions
- Patients must also take part in a structured support programme (wraparound care) including healthy eating and physical activity
- There is no need to contact your GP practice – eligible patients will be contacted directly by their practice or the NHS